PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade

Modern Pathology

Volumn 26, Issue 3, 2013, Pages 435-447

  Yoshimoto, Maisa ^a   Ding, Keyue ^a   Sweet, Joan M ^b   Ludkovski, Olga ^b   Trottier, Greg ^c   Song, Kyu S ^b   Joshua, Anthony M ^c   Fleshner, Neil E ^c   Squire, Jeremy A ^a,d   Evans, Andrew J ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d Pio XII Foundation   (Brazil)

Author keywords

genomic biomarkers; histologic heterogeneity; index tumor; prognosis; PTEN gene; TMPRSS2 ERG fusion

Indexed keywords

HYBRID PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; DISEASE ASSOCIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE DOSAGE; GENE FREQUENCY; GENE LOCUS; GENE REARRANGEMENT; GENETIC HETEROGENEITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN DEPLETION; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; BIOPSY, LARGE-CORE NEEDLE; CHI-SQUARE DISTRIBUTION; DOWN-REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS, MULTIPLE PRIMARY; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PROSTATECTOMY; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84875223342     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.162     Document Type: Article

References (76)

1. Nwosu V, Carpten J, Trent JM, et al. Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Mol Genet 2001;10:2313-2318.
2. Huland H, Graefen M, Haese A, et al. Prediction of tumor heterogeneity in localized prostate cancer. Urol Clin North Am 2002;29:213-222.
3. Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol 2010;41:781-793.
4. Grignon DJ. Unusual subtypes of prostate cancer. Mod Pathol 2004;17:316-327.
5. Wise AM, Stamey TA, McNeal JE, et al. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002;60: 264-269.
6. Villers A, McNeal JE, Freiha FS, et al. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992;70:2313-2318.
7. Allsbrook WC Jr, Mangold KA, Johnson MH, et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 2001;32:81-88.
8. Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-1242.
9. Arora R, Koch MO, Eble JN, et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004;100:2362-2366.
10. Fleshner N. Defining high-risk prostate cancer: current status. Can J Urol 2005;12(Suppl 1):14-17; discussion 94-6.
11. Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005;47:16-21.
12. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010;24:1967-2000.
13. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
14. Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008;21:1451-1460.
15. Yoshimoto M, Ludkovski O, Bayani J, et al. Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion. Genes Chromosomes Cancer 2007;46: 861-863.
16. Braun M, Scheble VJ, Menon R, et al. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology 2011;58:1028-1036.
17. Joshua AM, Evans A, Van der Kwast T, et al. Prostatic preneoplasia and beyond. Biochim Biophys Acta 2008; 1785:156-181.
18. Mehra R, Tomlins SA, Yu J, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008;68: 3584-3590.
19. Squire JA, Park PC, Yoshimoto M, et al. Prostate cancer as a model system for genetic diversity in tumors. Adv Cancer Res 2011;112:183-216.
20. Squire JA. TMPRSS2-ERG and PTEN loss in prostate cancer. Nat Genet 2009;41:509-510.
21. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009;15:4706-4711.
22. Magi-Galluzzi C, Tsusuki T, Elson P, et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 2011;71: 489-497.
23. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010;13: 228-237.
24. Ellett F, Kile BT, Lieschke GJ. The role of the ETS factor ERG in zebrafish vasculogenesis. Mech Dev 2009;126: 220-229.
25. Hawksworth D, Ravindranath L, Chen Y, et al. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 2010;13:311-315.
26. Schulz WA, Ingenwerth M, Djuidje CE, et al. Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation. BMC Cancer 2010;10:505.
27. Singh S, Barrett J, Sakata K, et al. ETS proteins and MMPs: partners in invasion and metastasis. Curr Drug Targets 2002;3:359-367.
28. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010;16:4325-4330.
29. Feilotter HE, Nagai MA, Boag AH, et al. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998;16:1743-1748.
30. Muller M, Rink K, Krause H, et al. PTEN/MMAC1 mutations in prostate cancer. Prostate Cancer Prostatic Dis 2000;3:S32.
31. Verhagen PC, van Duijn PW, Hermans KG, et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 2006;208:699-707.
32. Bednarz N, Eltze E, Semjonow A, et al. BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clin Cancer Res 2010;16:3340-3348.
33. Bismar TA, Yoshimoto M, Vollmer RT, et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int 2011; 107:477-485.
34. Hermans KG, van Alewijk DC, Veltman JA, et al. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines. Genes Chromosomes Cancer 2004; 39:171-184.
35. Ishkanian AS, Mallof CA, Ho J, et al. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 2009;69:1091-1100.
36. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007;67:8504-8510.
37. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007;97:678-685.
38. Yoshimoto M, Cutz JC, Nuin PA, et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 2006;169:128-137.
39. Reid AH, Attard G, Ambroisine L, et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010;102:678-684.
40. Sircar K, Yoshimoto M, Monzon FA, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009;218:505-513.
41. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
42. Holcomb IN, Young JM, Coleman IM, et al. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castrationresistant prostate cancer. Cancer Res 2009;69:7793-7802.
43. Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559-565.
44. Yoshimoto M, Ludkovski O, Degrace D, et al. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes Cancer 2012;51:149-160.
45. McMenamin ME, Soung P, Perera S, et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59:4291-4296.
46. Schmitz M, Grignard G, Margue C, et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007;120:1284-1292.
47. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41:619-624.
48. Sarker D, Reid AH, Yap TA, et al. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009;15:4799-4805.
49. Koksal IT, Dirice E, Yasar D, et al. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncol 2004;22: 307-312.
50. Ayala G, Thompson T, Yang G, et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004;10: 6572-6578.
51. Ohigashi T, Mizuno R, Nakashima J, et al. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate 2005;62:61-68.
52. Wang Y, Romigh T, He X, et al. Resveratrol regulates the PTEN/AKT pathway through androgen receptordependent and-independent mechanisms in prostate cancer cell lines. Hum Mol Genet 2010;19:4319-4329.
53. Barry M, Perner S, Demichelis F, et al. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007;70: 630-633.
54. Mehra R, Han B, Tomlins SA, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007;67:7991-7995.
55. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffinembedded tissue. J Mol Diagn 2006;8:141-151.
56. Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009;69:2912-2918.
57. Kawai T, Hiroi S, Nakanishi K, et al. Abnormalities in chromosome 17 and p53 in lung carcinoma cells detected by fluorescence in situ hybridization. Pathol Int 2004;54:413-419.
58. Korshunov A, Sycheva R, Gorelyshev S, et al. Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod Pathol 2005;18:1258-1263.
59. Mezzelani A, Alasio L, Bartoli C, et al. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates Br J Cancer 1999;80:519-525.
60. Fujii H, Ajioka Y, Kazami S, et al. Loss of heterozygosity in the clonal evolution of flat colorectal neoplasms. J Pathol 2002;197:298-306.
61. Saeed AI, Sharov V, White J, et al. TM4: a free, opensource system for microarray data management and analysis. Biotechniques 2003;34:374-378.
62. Bostwick DG, Shan A, Qian J, et al. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer 1998;83:1995-2002.
63. Ruijter ET, van de Kaa CA, Schalken JA, et al. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 1996;180:295-299.
64. Greene DR, Wheeler TM, Egawa S, et al. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 1991;146:1069-1076.
65. Villers A, Abecassis R, Baron JC, et al. [Extraperitoneal endoscopic lymph node dissection with insufflation in the staging of bladder and prostate cancer]. Prog Urol 1992;2:892-900.
66. McNeal JE, Price HM, Redwine EA, et al. Stage A versus stage B adenocarcinoma of the prostate: morphological comparison and biological significance. J Urol 1988;139:61-65.
67. Stamey TA, McNeal JE, Yemoto CM, et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281:1395-1400.
68. van der Kwast TH, Amin MB, Billis A, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens.Working group 2: T2 substaging and prostate cancer volume. Mod Pathol 2011;24:16-25.
69. Sakr WA, Macoska JA, Benson P, et al. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 1994;54:3273-3277.
70. Jenkins RB, Qian J, Lieber MM, et al. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997;57: 524-531.
71. Schmidt H, DeAngelis G, Eltze E, et al. Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res 2006;66:8959-8965.
72. Guo CC, Wang Y, Xiao L, et al. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers. Hum Pathol 2012;43: 644-649.
73. Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998;90: 233-237.
74. Macintosh CA, Stower M, Reid N, et al. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 1998;58:23-28.
75. Ruijter ET, Miller GJ, van de Kaa CA, et al. Molecular analysis of multifocal prostate cancer lesions. J Pathol 1999;188:271-277.
76. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008;21:67-75.